<DOC>
	<DOCNO>NCT02576236</DOCNO>
	<brief_summary>The H pylori infection remain public health problem . The eradication rate first line triple therapy ( PPI-amoxicillin-clarithromycin ) insufficient ( estimate 70 % ) due frequency resistance clarithromycin , reach 21 % France . Until , European French consensus recomended tofavor sequential therapy ( 5 day PPI-amoxicillin 5 day PPI-clarithromycin-metronidazole ) quadruple bismuth therapy ( 10 day PPI-tetracyclin , -metronidazole- bismuth ) . Studies country low prevalence clarithromycin resistance report eradication rate 85 % sequential therapy report low impact clarithromycin resistance effectiveness treatment . However , recent study suggest great impact clarithromycin resistance . Recent meta-analysis show empiric sequential therapy less efficacious concomitant quadruple therapy . Therefore , recent Maastricht V / Florence meeting October 7-8 2015 ) recommend abandon sequential therapy favor 14 day concomitant therapy first line order reach eradication rate &gt; 90 % . In multicenter randomize clinical trial ( HELICOSTIC 2010-2011 AO ICST 2009 ) , compare triple therapy guide result PCR test detects resistance clarithromycin levofloxacin ( HelicoDR ® ) empirical triple therapy ( PPI-amoxicillin-clarithromycin ) . 1384 patient among 526 infected patient enrol 10 center . The result 415 patient 73.1 % empirical treatment versus 85.5 % ( p &lt; 0.001 ) treatment guide PCR HelicoDR® . This study also demonstrate limit test HelicoDR® : onerous , possibility contamination , little practical contribution determination resistance quinolones . Moreover , show triple therapy efficiency could optimize increase duration 14 day increase dose PPI 40mg b.d ; .and eradication rate &gt; 90 % report susceptible clarithromycin strain . Adverse event less common optimized triple therapy concomitant quadruple therapy . The main objective compare efficacy optimized triple therapy guide result PCR test ( eradication rate 90 % hypothesize ) quadruple concomitant therapy ( eradication rate 90 % hypothesize ) . The secondary objective determine side effect optimize guided triple therapy well quadruple concomitant therapy France .</brief_summary>
	<brief_title>Therapeutic Trial Comparing Triple Therapy Guided PCR Detection Clarithromycin Resistance v Empiric Concomitant Quadruple Therapy Helicobacter Pylori Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Adult patient ≥ 18 year Hospitalized outpatient refer one participating center upper gastrointestinal endoscopy Who receive previous eradication treatment Willing participate sign inform consent . Finally patient bacteriologically document H. pylori infection ( PCR ) include . Patient already treat eradicate H pylorus No affiliation social insurance Person legal protection Refusal signing informed consent Patient include another trial medication Patient unable take oral medication ongoing Patient severe lifethreatening disease short term Contraindication PPIs , amoxicillin , metronidazole , clarithromycin , levofloxacin Patient treatment antibiotic PPI without possibility interruption 4 week Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Naïve patient</keyword>
	<keyword>Suspicion H pylori infection</keyword>
	<keyword>Endoscopy</keyword>
	<keyword>Antibiotics therapeutic strategy</keyword>
	<keyword>Urea breath test</keyword>
</DOC>